Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab

Bibliographic Details
Main Authors:	Falchook, Gerald S, Wheler, Jennifer J, Naing, Aung, Jackson, Edward F, Janku, Filip, Hong, David, Ng, Chaan S, Tannir, Nizar M, Lawhorn, Kristie N, Huang, Mei, Angelo, Laura S, Vishwamitra, Deeksha, Hess, Kenneth, Howard, Adrienne N, Parkhurst, Kristin L, Amin, Hesham M, Kurzrock, Razelle
Format:	Online
Language:	English
Published:	Impact Journals LLC 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279372/

id	pubmed-4279372
recordtype	oai_dc
spelling	pubmed-42793722015-01-06 Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab Falchook, Gerald S Wheler, Jennifer J Naing, Aung Jackson, Edward F Janku, Filip Hong, David Ng, Chaan S Tannir, Nizar M Lawhorn, Kristie N Huang, Mei Angelo, Laura S Vishwamitra, Deeksha Hess, Kenneth Howard, Adrienne N Parkhurst, Kristin L Amin, Hesham M Kurzrock, Razelle Clinical Research Paper Impact Journals LLC 2014-11-08 /pmc/articles/PMC4279372/ /pubmed/25373733 Text en Copyright: © 2014 Falchook et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Falchook, Gerald S Wheler, Jennifer J Naing, Aung Jackson, Edward F Janku, Filip Hong, David Ng, Chaan S Tannir, Nizar M Lawhorn, Kristie N Huang, Mei Angelo, Laura S Vishwamitra, Deeksha Hess, Kenneth Howard, Adrienne N Parkhurst, Kristin L Amin, Hesham M Kurzrock, Razelle
spellingShingle	Falchook, Gerald S Wheler, Jennifer J Naing, Aung Jackson, Edward F Janku, Filip Hong, David Ng, Chaan S Tannir, Nizar M Lawhorn, Kristie N Huang, Mei Angelo, Laura S Vishwamitra, Deeksha Hess, Kenneth Howard, Adrienne N Parkhurst, Kristin L Amin, Hesham M Kurzrock, Razelle Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab
author_facet	Falchook, Gerald S Wheler, Jennifer J Naing, Aung Jackson, Edward F Janku, Filip Hong, David Ng, Chaan S Tannir, Nizar M Lawhorn, Kristie N Huang, Mei Angelo, Laura S Vishwamitra, Deeksha Hess, Kenneth Howard, Adrienne N Parkhurst, Kristin L Amin, Hesham M Kurzrock, Razelle
author_sort	Falchook, Gerald S
title	Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab
title_short	Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab
title_full	Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab
title_fullStr	Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab
title_full_unstemmed	Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab
title_sort	targeting hypoxia-inducible factor-1α (hif-1α) in combination with antiangiogenic therapy: a phase i trial of bortezomib plus bevacizumab
description
publisher	Impact Journals LLC
publishDate	2014
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279372/
_version_	1613171635922141184

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab

Similar Items